natgillin/translations-raw huggingface dataset:
The apparent clearance (CL/F) of anastrozole, following oral administration, was not altered in volunteers with severe renal impairment (GFR <30ml/min) in study 1033IL/0018, consistent with the fact that anastrozole is eliminated primarily by metabolism.
V študiji 1033IL/0018 pri prostovoljcih s hudo okvaro ledvic (GFR<30 ml/min) se navidezni očistek (CL/F) anastrozola po peroralni uporabi ni spremenil, kar je skladno z dejstvom, da se anastrozol izloča predvsem s presnovo.
Arimidex is contraindicated during breastfeeding (see section 4.3).
Zdravilo Arimidex je kontraindicirano med obdobjem dojenja (glejte poglavje 4.3).
Arimidex should not be used in boys with growth hormone deficiency in addition to growth hormone treatment.
Zdravilo Arimidex se ne sme uporabljati pri fantih s pomanjkanjem rastnega hormona, ki se zdravijo z rastnim hormonom.
Section 5.1 Pharmacodynamic properties
Poglavje 5.1 Farmakodinamične lastnosti
Arimidex should not be used in premenopausal women.
Zdravilo Arimidex se ne sme uporabljati pri ženskah pred menopavzo.
The enzymes mediating metabolism of anastrozole have not been identified.
Encimi, ki povzročajo presnavljanje anastrozola, niso bili ugotovljeni.
Arimidex has not been investigated in breast cancer patients with severe renal impairment.
Zdravilo Arimidex ni bilo preučeno pri bolnikih z rakom dojke s hudo okvaro ledvic.
Co-administration of tamoxifen or estrogen-containing therapies with Arimidex should be avoided as this may diminish its pharmacological action (see section 4.5 and 5.1).
Treba se je izogibati sočasni uporabi tamoksifena ali zdravil, ki vsebujejo estrogen, in zdravila Arimidex, saj lahko zmanjšajo njegovo farmakološko delovanje (glejte poglavji 4.5 in 5.1).
One statement proposed in relation to the SABRE study mentioned a neutral effect of Arimidex on plasma lipids in patients concomitantly treated with risendronate.
Predlagana izjava v zvezi s študijo SABRE je navajala, da pri bolnikih, ki sočasno jemljejo risendronat, zdravilo Arimidex nima vpliva na lipide v plazmi.
Co-administration of tamoxifen or estrogen-containing therapies with Arimidex should be avoided as this may diminish its pharmacological action (see section 4.4 and 5.1).
Treba se je izogibati sočasni uporabi tamoksifena ali zdravil, ki vsebujejo estrogen, in zdravila Arimidex, saj lahko zmanjšajo njegovo farmakološko delovanje (glejte poglavji 4.4 in 5.1).
In one country the SPC contained the warning ‘slight increases in total cholesterol have been observed in patients treated with Arimidex.
V eni državi je povzetek glavnih značilnosti zdravila vseboval opozorilo: „pri bolnikih, zdravljenih z zdravilom Arimidex, je bilo opaženo majhno povišanje skupnega holesterola.
• the summary of products characteristics, labelling and package leaflet proposed by the marketing authorisation holders have been assessed based on the documentation submitted and the scientific discussion within the Committee the CHMP has recommended the amendment of the marketing authorisations for which the summary of product characteristics, labelling and package leaflet are set out in Annex III for Arimidex.
• Povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo, ki so jih predlagali imetniki dovoljenja za promet z zdravilom, so bili ocenjeni na osnovi predložene dokumentacije in strokovne razprave v Odboru.
Grounds for amendment of the summary of product characteristics, labelling and package leaflet
Podlaga za dopolnilo povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo
Caution is advised in patients with moderate to severe hepatic impairment (see section 4.4).
Pri zdravljenju bolnikov z zmernim do hudo okvaro jeter je potrebna previdnost (glejte poglavje 4.4).
The CHMP further asked the MAH to include information present in the SPC of some countries on the occurrence of carpal tunnel syndrome in clinical trials.
CHMP je imetnika dovoljenja za promet tudi zaprosil, da vključi informacije o pojavljanju sindroma zapestnega kanala v kliničnih preskušanjih, ki so bile navedene v povzetkih glavnih značilnosti zdravila nekaterih držav.
monograph of anastrozole which is currently under revision.
Predlagatelj bo moral zagotoviti usklajenost z ustrezno monografijo Evropske farmakopeje za anastrozol, ki je trenutno v reviziji.
The CHMP noted the wording proposed by the MAH for the harmonisation of this section, which included a statement to the fact that antipyridine and cimetidine clinical interaction studies indicate that significant drug interactions mediated by cytochrome P450 are unlikely.
Poglavje 4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij CHMP je preučil predlagano besedilo imetnika dovoljenja za promet z zdravilom za uskladitev tega poglavja, ki je vključevalo izjavo, da so klinične študije medsebojnega delovanja z antipiridinom in cimetidinom pokazale, da pomembno medsebojno delovanje zdravil zaradi citokroma P450 ni verjetno.
There are no data on the use of Arimidex during lactation.
Podatkov o uporabi zdravila Arimidex med dojenjem ni.
The CHMP noted and agreed with the MAH proposal for this section:
CHMP je preučil in potrdil predlog imetnika dovoljenja za promet z zdravilom glede tega poglavja:
A recommended duration of treatment of 5 years is justified by the results of the ATAC study, in which the efficacy of adjuvant treatment with Arimidex was compared to adjuvant treatment with tamoxifen.
Rezultati študije ATAC, v kateri so primerjali učinkovitost dodatnega zdravljenja z zdravilom Arimidex in učinkovitost dodatnega zdravljenja s tamoksifenom, so utemeljili priporočeno petletno obdobje zdravljenja.
• Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women.
• Dodatno zdravljenje žensk po menopavzi z zgodnjim invazivnim rakom dojke, pozitivnim na hormonske receptorje.
The CHMP supported the proposal from the MAH not to include this warning in the harmonised wording, as the published clinical studies do not indicate a significant increase in total cholesterol or LDL-C, or a decrease in HDL-C after Arimidex use.
Pri bolnikih s potrjeno boleznijo srca ali dejavniki tveganja je treba spremljati vrednost lipidov in jih zdraviti v skladu z veljavnimi smernicami.“ CHMP se je strinjal s predlogom imetnika dovoljenja za promet z zdravilom, da se to opozorilo ne vključi v usklajeno besedilo, saj objavljene klinične študije ne kažejo na pomembno povečanje skupnega holesterola ali holesterola LDL oz. zmanjšanje holesterola HDL po uporabi zdravila Arimidex.
The changes to the SPC, when relevant, were also reflected in the package leaflet.
Spremembe v povzetku glavnih značilnosti zdravila se odražajo tudi v navodilu za uporabo, kjer je to primerno.
• Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women.
• Zdravljenje žensk po menopavzi z napredovalim rakom dojke, pozitivnim na hormonske receptorje
No dose change is recommended in patients with mild or moderate renal impairment.
Pri bolnikih z blago ali zmerno okvaro ledvic odmerka ni treba spreminjati.
The final adopted wording for this section is as follows:
Ob upoštevanju naslednjega:
ATC vet code: QP54AA55.
oznaka ATC vet: QP54AA55.
On the day of treatment, treated animals should not be permitted to sleep in the same bed as their owner, especially children.
Na dan zdravljenja živali ne smejo spati v isti postelji kot njihov lastnik, še zlasti ne z otroci.
Squeeze the pipette firmly 3-4 times to empty the contents in one spot.
Merilno kapalko 3 do 4 krat stisnemo, da se vsebina izprazni na enem mestu.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 26/04/2019
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 26/04/2019
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Če opazite kakršne koli stranske učinke, tudi tiste, ki niso navedeni v tem navodilu za uporabo ali mislite, da zdravilo ni delovalo,, obvestite svojega veterinarja.
EXPIRY DATE EXP {month/year}
EXP {mesec/leto}
Clear, colourless to yellow solution.
Bistra, brezbarvna do rumena raztopina.
The periodic safety update report (PSUR) submissions shall be synchronised and submitted at the same frequency as for the originator product.
Oddaje rednih posodobljenih poročil o varnosti zdravila (PSUR) je treba sinhronizirati in oddati enako pogosto kot to velja za zdravilo originatorja.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.emea.europa.eu/).
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) (http://www.ema.europa.eu/.)
The veterinary medicinal product is exclusively indicated when use against ticks and one or more of the other target parasites is indicated at the same time.
Zdravilo je izključno indicirano kadar je indicirana sočasna uporaba proti klopom in proti enemu ali več ciljnim parazitom.
Do not use in cats that are suffering from concomitant disease, or are debilitated and underweight (for size and age).
Ne uporabite pri mačkah, ki imajo sočasna obolenja, ali so močno oslabljene ali prelahke (glede na velikost in starost).
Store below 30 °C.
Shranjujte pri temperaturi pod 30 °C.
Seek further veterinary examination 30 days after treatment to determine whether a second administration is necessary.
30 dni po prvem zdravljenju naj veterinar ponovno pregleda žival, da se določi ali je potreben drugi odmerek.
Ticks must attach to the host and commence feeding in order to be exposed to sarolaner.
Klopi se morajo pritrditi na gostitelja in se začeti hraniti, da bi bili izpostavljeni surolanerju.
People with sensitive skin or known allergy to veterinary medicinal products of this type should handle the veterinary medicinal product with caution.
Osebe z občutljivo kožo ali znano alergijo na tovrstna zdravila naj zdravilo dajejo previdno.
During clinical field testing, no interactions between this veterinary medicinal product and routinely used veterinary medicinal products were observed.
Med kliničnim preskušanjem na terenu niso opazili nikakršnega medsebojnega delovanja med tem zdravilom in drugimi rutinsko uporabljenimi zdravili.
Bodyweight of cat (kg)
Telesna teža mačke (kg)
For ear mite treatment, do not apply directly to the ear canal.
Za zdravljenje ušesnih garij ne dajajte zdravila direktno v ušesni kanal.
Keep treated animals away from fires and other sources of ignition for at least 30 minutes or until the hair coat is dry.
Zdravljene živali naj se ne zadržujejo v bližini ognja in drugih vnetljivih virov najmanj 30 minut ali dokler dlaka ni suha.
Identification of selamectin metabolites in faeces indicated that metabolic clearance also contributes to the elimination.
Identifikacija metabolitov selamektina v blatu dokazuje, da metabolični očistek tudi prispeva k izločanju.
- The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
- Zdravilo se lahko uporablja kot del strategije zdravljenja alergijskega dermatitisa, ki ga povzročajo bolhe (flea allergy dermatitis (FAD).
MARKETING AUTHORISATION NUMBER(S) EU/2/19/238/001-003
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/19/238/001-003
The need for and frequency of re-treatment should be in accordance with the advice of the prescribing veterinarian.
Potreba po zdravljenju in pogostnost zdravljenja in ponovnega zdravljenja mora biti v skladu z navodili veterinarja.
Felisecto Plus should not enter water courses as this may be dangerous to aquatic organisms.
Felisecto Plus ne sme priti v vodotoke, ker je lahko nevaren za ribe in druge vodne organizme.
Avoid direct contact with treated animals until the application area is dry.
Izogibajte se neposrednemu stiku z zdravljenimi živalmi, dokler območje nanosa ni suho.
MARKETING AUTHORISATION NUMBER(S) EU/2/19/238/001 (3 x 0.25 ml) EU/2/19/238/002 (3 x 0.5 ml) EU/2/19/238/003 (3 x 1 ml)
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/19/238/001 (3 x 0.25 ml) EU/2/19/238/002 (3 x 0.5 ml) EU/2/19/238/003 (3 x 1 ml)
Do not use this veterinary medicinal product after the expiry date which is stated on the blister after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na pretisnerm omotu po {EXP }.
It is recommended to treat animals in the evening.
Priporoča se zdravljenje zvečer.
Containers and residual contents should be disposed of along with collected domestic refuse to avoid contamination of any water courses.
Vsebniki in ostanki vsebine se morajo odlagati v sistem zbiranja gospodinjskih odpadkov, da se izognemo onesnaženju vseh vodnih virov.
SPECIAL STORAGE CONDITIONS Store below 30 °C.
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi pod 30 °C.
Shelf life of the veterinary medicinal product as packaged for sale: 30 months.
Rok uporabnosti zdravila v pakiranju za prodajo: 30 mesecev.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali) - pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali) - občasni (pri več kot 1, toda manj kot 10 živali od 1.000 zdravljenih živali) - redki (pri več kot 1, toda manj kot 10 živali od 10.000 zdravljenih živali) - zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri).
This inhibits the electrical activity of nerve cells in nematodes and muscle cells in arthropods leading to their paralysis and/or death.
To zavira električno aktivnost živčnih celic nematodov in mišičnih celic artropodov in vodi k njihovi paralizi in/ali smrti.
Pharmacotherapeutic group: Antiparasitic products, insecticides and repellents, macrocyclic lactones, combinations.
Farmakoterapevtska skupina: antiparazitiki, insekticidi in repelenti, makrociklični laktoni, kombinacije.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
DATUM ZADNJE ODOBRITVE NAVODIL ZA UPORABO Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) http://www.ema.europa.eu/.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
Ne uporabite v primeru preobčutljivosti na aktivni učinkovini ali na katero koli pomožno snov.
Following topical administration of the Felisecto Plus both selamectin and sarolaner are well absorbed with bioavailability mean values of 40.5% and 57.9%, respectively and distribute systemically.
Po lokalem nanosu Felisecto Plus se oba selamektin in sarolaner dobro resorbirata in dosežeta povprečno biološko razpoložljivost 40,5% in 57,9% ter se sistemsko porazdelita.
Ticks need to start feeding on the host to become exposed to sarolaner; therefore, the transmission of infectious tick-borne diseases cannot be excluded.
Klopi se morajo začeti hraniti na gostitelju, da so izpostavljeni surolanerju, zato prenos infekcijskih bolezni, ki so prenosljive s klopi, ni izključen.
Use only according to the benefit-risk assessment by the prescribing veterinarian.
Uporabite le v skladu z oceno razmerja korist/tveganje odgovornega veterinarja.
as well as several tick species such as Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, and Rhipicephalus sanguineus.
kot tudi na številne vrste klopov kot so Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus in Rhipicephalus sanguineus.
Selamectin may adversely affect aquatic organisms.
Selamektin lahko negativno učinkuje na vodne organizme.
No clinically significant adverse reactions were observed in kittens from 8 weeks of age treated with up to 5 times the maximum recommended dose of the product for up to 8 consecutive treatments at 28 day intervals, apart from a single cat administered 5 times the maximum dose that displayed transient hypersensitivity to touch, piloerection, mydriasis and mild tremor which resolved without treatment.
Nobenih klinično pomembnih neželenih učinkov niso opazili pri mačjih mladičih starih najmanj 8 tednov zdravljenih s petkratnim priporočenim največjim odmerkom, v osmih zaporednih zdravljenjih z 28 dnevnimi intervali, z izjemo ene mačke, ki ji je bil dan 5 kratni največji odmerek in je kazala prehodne znake preobčutljivost na dotik, naježeno dlako, midrijazo in rahlo tresenje in so izzveneli brez zdravljenja.
The product kills adult fleas before they lay eggs for 5 weeks.
Zdravilo ubija odrasle bolhe preden bi izlegle nova jajčeca vsaj 5 tednov.
However, selamectin is considered safe for use in breeding, pregnant and lactating cats.
Kljub temu se selamektin smatra varen za uporabo pri vzrejnih in brejih mačkah in mačkah v laktaciji.
It is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more, living in countries where a vector exists should be tested for existing adult heartworm infection before beginning preventive use with the veterinary medicinal product.
Priporoča se, v skladu z dobro veterinarsko prakso, da se vse živali stare 6 mesecev in več, ki živijo v državah, kjer obstaja prenašalec mikrofilarij, pred pričetkom preventivne uporabe zdravila, testira na prisotnost infestacije z odraslimi oblikami Dirofilarie immitis.
Do not administer orally or parenterally.
Zdravila se ne sme dajati peroralno ali parenteralno.
Whilst not routinely indicated, the potential benefits of performing periodic testing for heartworm infection in individual cases should be considered by the responsible veterinarian.
Čeprav ni rutinsko indicirano, naj veterinar v posameznih primerih oceni morebitno korist izvajanja periodičnega testiranja na prisotnost infestacije s srčno glisto.
Selamectin is a semi-synthetic compound of the avermectin class.
Selamektin je polsintetična komponenta iz skupine avermektinov.
While the safety of sarolaner has not been evaluated in breeding, pregnant or lactating cats, laboratory studies with sarolaner in rats and rabbits have not produced any evidence of teratogenic effects.
Medtem ko varnost sarolanerja ni bila ugotovljena pri vzrejnih in brejih mačkah ter mačkah v laktaciji pa z laboratorijskimi študijami na podganah in kuncih niso bili dokazani teratogeni učinki.
When replacing another heartworm preventive product in a heartworm disease prevention programme, the first dose of the product must be given within a month of the last dose of the former veterinary medicinal product.
Kadar zamenjamo z drugim preventivnim zdravilom za srčno glistavost, moramo prvi odmerek dati v obdobju enega meseca po zadnjem dajanju prejšnjega zdravila.
If a dose is missed and a monthly interval between dosing is exceeded, then immediate administration of the product and resumption of monthly dosing will minimise the opportunity for the development of adult heartworms.
Če smo kakšen odmerek izpustili in mesečni presledek med dvema odmerkoma prekoračili, bomo s takojšnjim dajanjem zdravila in s ponovnim mesečnim odmerjanjem možnost razvoja odraslih oblik parazita zmanjšali na najmanjšo možno mero.
Avoid eye contact including hand-to-eye-contact.
Izogibajte se stiku z očmi vključno s stikom oči z rokami.
Special precautions for storage
POSEBNA NAVODILA ZA SHRANJEVANJE
The administration to animals with adult heartworm infection did not pose safety concerns.
Dajanje zdravila živalim z znano infestacijo z odraslimi oblikami srčne glistavosti ni predstavljala pomislekov glede varnosti.
Sarolaner does not interact with known insecticidal binding sites of nicotinic or other GABAergic insecticides such as neonicotinoids, fiproles, milbemycins, avermectins, and cyclodienes.
Sarolaner ne deluje medsebojno z znanimi insekticidnimi mesti vezave nikotinskih in drugih GABAergičnih insekticidov kot so neonikotinoidi, fiproli, milbemicini, avermektini in ciklodieni.
Children are not allowed to play with treated cats for 4 hours after treatment.
Otroci ne smejo priti v stik z zdravljenimi živalmi še 4 ure po nanosu zdravila.
- Treatment of biting lice infestations (Felicola subrostratus).
- Zdravljenje infestacij z ušmi (Felicola subrostratus).
Use of this veterinary medicinal product is indicated in cats aged at least 8 weeks old and weighing at least 1.25 kg bodyweight.
Zdravilo se lahko daje mačkam, ki so stare vsaj 8 tednov ali tehtajo vsaj 1,25 kg.
MANUFACTURER'S BATCH NUMBER Lot {number}
PROIZVAJALČEVA ŠTEVILKA SERIJE Lot {številka}
If accidental eye exposure occurs, flush the eyes immediately with water and seek medical attention.
Če pride zdravilo pomotoma v oči, jih je treba takoj izpirati z obilo vode in poiskati zdravniško pomoč.
The product may be administered year-round or at least within one month of the animal's first exposure to mosquitoes and monthly thereafter until the end of the mosquito season.
Zdravilo se lahko daje vse leto ali vsaj v obdobju enega meseca po prvi izpostavitvi živali komarjem, nato pa vsak mesec, dokler traja njihova sezona.
This veterinary medicinal product is not effective against adult D. immitis.
Zdravilo ne učinkuje na odrasle oblike D. immitis.
The product is available in packs of three pipettes (all pipette sizes) placed in cardboard boxes.
Zdravilo je na voljo v pakiranju s tremi merilnimi kapalkami (vse velikosti merilnih kapalk) v kartonskih škatlah.
Sarolaner is an acaricide and insecticide belonging to the isoxazoline family.
Sarolaner je akaricid in insekticid iz skupine izoksazolinov.
- For the treatment and prevention of flea infestations (Ctenocephalides spp.).
- Za zdravljenje in preprečevanje infestacij z bolhami (Ctenocephalides spp.).
In cats, selamectin and sarolaner are low clearance compounds with long half-life values, 12.5 days and 41.5 days respectively, following topical administration.
Pri mačkah sta selamektin in sarolaner spojini z nizkim očistkom in dolgo razpolovno dobo 12,5 dni in 41,5 dni po topikalnem nanosu.
- Treatment of tick infestations.
- Zdravljenje infestacij s klopi.
Selamectin paralyzes and/or kills a wide range of invertebrate parasites through interference with their chloride channel conductance causing disruption of normal neurotransmission.
Selamektin povzroča paralizo in/ali pogin širokega spektra parazitov (nevretenčarjev) z oviranjem prevodnosti kloridnih kanalov, kar povzroči motnje v normalni nevrotransmisiji.
Fleas and ticks
Bolhe in klopi
The primary target of action of sarolaner in insects and acarines is functional blockade of ligand-gated chloride channels (GABA-receptors and glutamate-receptors).
Primarni cilj delovanja sarolanerja pri insektih in pršicah je funkcionalna blokada od ligandov odvisnih kloridnih kanalov (GABA receptorji in receptorji glutamata).
Therefore, it effectively breaks the flea life cycle by killing adults (on the animal), preventing the hatching of eggs (on the animal and in its environment) and by killing larvae (environment only).
Razvojni krog bolhe prekine tako, da ubije odrasle bolhe (na živali), prepreči izleganje jajčec (na živali in v okolici) in ubije ličinke (v okolici).
The final dose must be given within one month after the last exposure to mosquitoes.
Zadnji odmerek je treba dati v obdobju enega meseca po zadnjem stiku živali s komarji.
Prevention of heartworm disease
Preprečevanje obolenja srčne glistavosti
It is important to apply the dose as indicated to prevent the animal from licking and ingesting the product.
Pomembno je, da se zdravilo daje v skladu z navodili za uporabo, da se prepreči lizanje in zaužitje zdravila.
BATCH NUMBER Lot {number}
ŠTEVILKA SERIJE Lot {številka}